Jonathan M. Blevitt
Research Subjects
Jonathan M. Blevitt has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Aaron N. Patrick
Johnson & Johnson Innovative Medicine, 1400 McKean Road, Spring House, Pennsylvania 19477, United States
1 shared publicationAnnie X. Liu
Johnson & Johnson Innovative Medicine, 1400 McKean Road, Spring House, Pennsylvania 19477, United States
1 shared publicationAnthony A. Armstrong
Johnson & Johnson Innovative Medicine, 1400 McKean Road, Spring House, Pennsylvania 19477, United States
1 shared publicationAnthony D. Keefe
X-Chem, Inc, 100 Beaver Street, Waltham, Massachusetts 02453, United States
1 shared publicationAvery Hunt
X-Chem, Inc, 100 Beaver Street, Waltham, Massachusetts 02453, United States
1 shared publicationChristoper D. Hupp
X-Chem, Inc, 100 Beaver Street, Waltham, Massachusetts 02453, United States
1 shared publication
Latest Publications
- 6 October 2025
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 16 (11) , 2301-2308
A Novel Small Molecule Allosteric Inhibitor of IL-17A from a DNA-Encoded Library
A novel series of inhibitors of the interaction of IL-17A with its cognate receptor has been discovered using DNA-encoded library (DEL) technology. The lead compound (JNJ627, Compound 1) of the series occupies the interior interface of the IL-17A homodimer and disables receptor binding. The mechanism of action involves allosteric disruption of the IL-17A quaternary structure to prevent adoption of the receptor-binding conformation, rather than direct orthosteric inhibition at the receptor-binding site. Molecules of this series exhibit remarkably slow on-rate kinetics and potent inhibition of IL-17A signaling in human primary cells.
- 6 October 2025
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 16 (11) , 2301-2308
A Novel Small Molecule Allosteric Inhibitor of IL-17A from a DNA-Encoded Library
A novel series of inhibitors of the interaction of IL-17A with its cognate receptor has been discovered using DNA-encoded library (DEL) technology. The lead compound (JNJ627, Compound 1) of the series occupies the interior interface of the IL-17A homodimer and disables receptor binding. The mechanism of action involves allosteric disruption of the IL-17A quaternary structure to prevent adoption of the receptor-binding conformation, rather than direct orthosteric inhibition at the receptor-binding site. Molecules of this series exhibit remarkably slow on-rate kinetics and potent inhibition of IL-17A signaling in human primary cells.